- Conditions
- Multiple Sclerosis (MS)
- Interventions
- Alemtuzumab
- Drug
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 2
- States / cities
- Dallas, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 82
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Rheumatoid Arthritis
- Interventions
- natalizumab, placebo
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 299 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2004
- U.S. locations
- 10
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Escondido, California + 7 more
- Conditions
- Multiple Sclerosis
- Interventions
- Cladribine
- Drug
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 2
- States / cities
- Overland Park, Kansas • Dallas, Texas
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- Interventions
- Natalizumab, Placebo
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 900 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2005
- U.S. locations
- 14
- States / cities
- Scottsdale, Arizona • Berkeley, California • Davis, California + 11 more
- Conditions
- Relapsing-Remitting Multiple Sclerosis (RRMS)
- Interventions
- Daclizumab
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 3
- States / cities
- Tampa, Florida • Des Moines, Iowa • Milwaukee, Wisconsin
- Conditions
- Progressive Multifocal Leukoencephalopathy, Multiple Sclerosis
- Interventions
- Not listed
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Multiple Sclerosis
- Interventions
- Hematopoietic Stem Cell Therapy, Standard treatment with a conventional drug
- Procedure · Drug
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2019
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Relapsing Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
- Interventions
- Autologous Hematopoietic Stem Cell Transplantation, Best Available Therapy (BAT)
- Procedure · Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 156 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2029
- U.S. locations
- 23
- States / cities
- Palo Alto, California • Aurora, Colorado • Evanston, Illinois + 18 more
- Conditions
- Multiple Myeloma
- Interventions
- BG00002 (natalizumab)
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 2
- States / cities
- Scottsdale, Arizona • Rochester, Minnesota
- Conditions
- Acute Ischemic Stroke
- Interventions
- natalizumab, Placebo
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 161 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 19
- States / cities
- San Diego, California • Gainesville, Florida • Kansas City, Kansas + 16 more
- Conditions
- Multiple Sclerosis
- Interventions
- Diroximel Fumarate, Avonex, Tysabri, Dimethyl Fumarate
- Drug · Biological
- Lead sponsor
- Biogen
- Industry
- Eligibility
- Female only
- Enrollment
- 908 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2032
- U.S. locations
- 2
- States / cities
- Aurora, Colorado • Durham, North Carolina
- Conditions
- Crohn's Disease, Prenatal Exposure, Multiple Sclerosis, Pregnancy
- Interventions
- Not listed
- Lead sponsor
- Biogen
- Industry
- Eligibility
- Female only
- Enrollment
- 376 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 1
- States / cities
- Morgantown, West Virginia
- Conditions
- Multiple Sclerosis, Covid19
- Interventions
- Not listed
- Lead sponsor
- St. Barnabas Medical Center
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 45 participants
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Livingston, New Jersey
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- Interventions
- BG00002 (natalizumab)
- Biological
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 404 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 53
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 46 more
- Conditions
- Multiple Sclerosis
- Interventions
- Natalizumab
- Drug
- Lead sponsor
- State University of New York at Buffalo
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2023
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Relapsing Remitting Multiple Sclerosis
- Interventions
- MSDX Complex-1 Biomarker test
- Other
- Lead sponsor
- MSDx, Inc.
- Industry
- Eligibility
- 45 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012
- U.S. locations
- 1
- States / cities
- Tucson, Arizona
- Conditions
- Secondary Progressive Multiple Sclerosis
- Interventions
- natalizumab, Placebo
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years to 58 Years
- Enrollment
- 889 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 35
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Fullerton, California + 29 more
- Conditions
- Relapsing-remitting Multiple Sclerosis (RRMS)
- Interventions
- BeCare application
- Device
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 18 Years to 60 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Crohn's Disease
- Interventions
- natalizumab
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2004
- U.S. locations
- 11
- States / cities
- Los Angeles, California • Hartford, Connecticut • Miami, Florida + 7 more
- Conditions
- Multiple Sclerosis
- Interventions
- BG00002 (natalizumab), keyhole limpet hemocyanin (KLH), tetanus diphtheria toxoid vaccine (Td)
- Biological
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 10
- States / cities
- Fullerton, California • Centennial, Colorado • Farmington Hills, Michigan + 7 more
- Conditions
- Multiple Sclerosis
- Interventions
- Not listed
- Lead sponsor
- Biogen
- Industry
- Eligibility
- Not listed
- Enrollment
- 2,207 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2015
- U.S. locations
- 1
- States / cities
- Kansas City, Missouri
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- Interventions
- Natalizumab (Tysabri)
- Drug
- Lead sponsor
- Cornerstone Health Care, PA
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 3
- States / cities
- Patchogue, New York • High Point, North Carolina • Portland, Oregon
- Conditions
- Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
- Interventions
- Dosing Interruption of Natalizumab
- Drug
- Lead sponsor
- Berkovich, Regina MD, PhD Inc.
- Other
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- West Hollywood, California
- Conditions
- Multiple Sclerosis
- Interventions
- Natalizumab
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Cambridge, Massachusetts